Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Favipiravir and/or Nitazoxanide: a Randomized, Double-blind, Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 (FANTAZE)

NCT04918927 is registered in ClinicalTrials.gov with Coordinación de Investigación en Salud, Mexico as lead sponsor.

NCT NCT04918927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04918927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Favipiravir and/or Nitazoxanide: a Randomized, Double-blind, Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 (FANTAZE)
Lead sponsor
Coordinación de Investigación en Salud, Mexico
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2021
Completion date
March 21, 2023
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19